Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic BRCA1/2 gene mutation. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all patients retrospectively.

Eligible patients will receive treatment with olaparib + LHRH agonist. Following 6 months of therapy, patients will undergo RP with mandatory lymph node dissection. The lymph node dissection template will be at the discretion of the treating urologist. RP specimens will undergo pathology blinded independent central review. Following RP, patients will be followed for testosterone recovery and PSA progression.

Study Overview

• Status: Recruiting
• Conditions: Prostate Cancer; BRCA1 Mutation; BRCA2 Mutation; Prostatic Adenocarcinoma; High-Risk Cancer
• Intervention / Treatment: Drug: Olaparib; Drug: LHRH agonist

• Study Type: Interventional
• Enrollment (Estimated): 32
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Gabrielle Tiggs; Phone Number: 62 317-634-5842; Email: gtiggs@hoosiercancer.org
• Study Contact Backup: Name: Rana R. McKay, MD; Phone Number: 858-822-6185; Email: rmckay@ucsd.edu

Study Locations

• United States
  • California
    • La Jolla, California, United States, 92093
      • Recruiting
      • University of California San Diego - Moores Cancer Center
      • Contact: Bianca Mogannam; Email: bmogannam@health.ucsd.edu
      • Principal Investigator: Rana R McKay
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Recruiting
      • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
      • Principal Investigator: Channing Paller, MD
      • Contact: Amina Touma; Email: atouma1@jhmi.edu
  • New York
    • New York, New York, United States, 10065
      • Recruiting
      • Memorial Sloan Kettering Cancer Center
      • Contact: Christine Moon; Phone Number: 646-422-4600; Email: moonc@mskcc.org
      • Principal Investigator: Deaglan McHugh, MD
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • Recruiting
      • Penn Medicine Abramson Cancer Center
      • Contact: Jennifer Louie; Email: Jennifer.Louie2@pennmedicine.upenn.edu
      • Principal Investigator: Naomi Balzar Haas, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this study:

• Written informed consent and HIPAA authorization for release of personal health information prior to registration.
• Age ≥ 18 years at the time of consent.
• T stage 1-3 prostatic adenocarcinoma per AJCC staging manual Ed8.
• Histologically confirmed adenocarcinoma of the prostate without histological variants comprising >50% of the sample. Patients with intraductal carcinoma are eligible.
• Must have 3 core biopsies involved with cancer (a minimum of 6 core biopsies must be obtained). Prostate biopsy must be within 7 months from registration. Less than 3 core biopsies are allowed if the patient has >1 cm or T3 disease on magnetic resonance imaging (MRI).

• Localized unfavorable intermediate or high-risk prostate cancer patients. Patients must have at least one of the following features:

  • Gleason ≥ 4+3 (grade group 3, 4, 5) OR
  • PSA > 20 ng/dL OR
  • T3 disease NOTE: Patients with intraductal carcinoma are eligible independent of Gleason score, PSA and T stage.
• Must have evidence of germline or somatic BRCA1/2 gene alteration via standard of care CLIA based assay detection. Testing will be confirmed centrally but results of central testing not required for enrollment.
• No evidence of metastatic disease as determined by radionuclide bone scan and CT/MRI. Lymph nodes must be less than 20 mm in the short (transverse) axis.
• Participants must be candidates for RP and considered surgically resectable by urologic evaluation.
• ECOG Performance Status of 0-1 within 28 days prior to registration.

• Demonstrate adequate organ function as defined below. All screening labs to be obtained within 28 days prior to registration.

  • White blood cell count ≥ 3,000/mcL
  • Absolute neutrophil count ≥ 1,500/mcL
  • Hemoglobin ≥ 10 g/dL with no transfusion support in the past 28 days
  • Platelets ≥ 100,000/mcL
  • Aspartate aminotransferase, alanine aminotransferase, and total bilirubin ≤ 1.5 x Institutional upper limit of normal
  • Calculated creatinine clearance ≥ 51 mL/min based on Cockcroft-Gault formula or 24 hour urine. NOTE: See the protocol for Cockcroft-Gault formula or 24 hour urine.
• Life expectancy≥ 16 weeks.
• Subjects must use a condom plus spermicide beginning prior to treatment Cycle 1 Day 1, during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. See protocol for additional details.
• As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

• Active infection requiring systemic therapy.
• Prior treatments not allowed: hormone therapy for prostate cancer including orchiectomy, antiandrogens (including first-generation antiandrogens, enzalutamide, apalutamide and others), CYP17 inhibitors (including abiraterone, TAK-700, galeterone, ketoconazole, and others), estrogens and radiation therapy. Prior bicalutamide is allowed if taken for < 4 weeks prior to registration and there is a washout period of 2 weeks prior to the initiation of study treatment. LHRH agonist/antagonist therapy is allowed if begun within 4 weeks of registration. Prior 5-alpha reductase inhibitors are allowed but require a washout period of 2 weeks to initiation of study treatment.
• Prior treatment with a PARP inhibitor.
• Hypogonadism or severe androgen deficiency as defined by screening serum testosterone < 200 ng/dL.

• Clinically significant acute infection requiring systemic antibacterial, antifungal, or antiviral therapy including:

  • tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice).
  • Known active hepatitis infection, positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody at screening. Testing is not required unless there was a prior known positive hepatitis B or C test or hepatitis is suspected at screening. Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Known to have tested positive for human immunodeficiency virus (HIV) unless currently on effective anti-retroviral therapy with an undetectable viral load within 6 months.
• Severe hepatic impairment (Child-Pugh Class C).
• Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
• Pre-existing condition that warrants long-term corticosteroid use greater than the equivalent of 10 mg prednisone daily. Physiologic replacement is permitted. Topical, intra-articular steroids or inhaled corticosteroids are permitted.

• Active cardiac disease, defined as:

  • Myocardial infarction within 6 months of study treatment.
  • Uncontrolled angina within 3 months of study treatment.
  • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless an echocardiogram performed within 3 months of the screening visit results in a left ventricular ejection fraction that is ≥ 45%.
  • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes)
  • Other clinically significant cardiovascular disease within 6 months of registration.
• Uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation >500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.
• Individuals with a history of another malignancy are not eligible if the cancer is under active treatment or the cancer can be seen on radiology scans or if they are off cancer treatment but in the opinion of their oncologist have a high risk of relapse within 5 years.
• Major surgery within 4 weeks from start of treatment. Subjects must have recovered from any effects as the surgery as assessed by investigator discretion.
• Treatment with any investigational drug within 28 days prior to registration.
• Persistent toxicities Grade > 2 caused by previous cancer therapy (per Common Terminology Criteria for Adverse Event (CTCAE)).
• Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.
• Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorders that prohibits obtaining informed consent.
• Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.
• Concomitant use of known strong CYP3A inhibitors. The required washout period prior to starting olaparib is 2 weeks.
• Concomitant use of known strong or moderate CYP3A inducers. The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
• Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
• Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable, for timing refer to the protocol).
• Patients with a known hypersensitivity to olaparib or any of the excipients of the product.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Investigational Group; 300 mg of olaparib taken orally twice a day for 6 cycles (approximately 6 months). There are 30 days in a cycle. Olaparib will be taken with an LHRH agonist (leuprolide, triptorelin, or goserlin). This choice of therapy will be taken for a total of 180 days per institutional standards. After 6 cycles of neoadjuvant therapy, patients will undergo a radical prostatectomy (RP). After RP, patients will be followed for testosterone recovery and PSA progression.

Drug: Olaparib; 300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles); Other Names: Lynparza; Drug: LHRH agonist; Total duration of therapy will be for 180 days with use of agent as per institutional standards; Other Names: Leuprolide; Goserelin; Triptorelin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathological Complete Response (pCR) rate	Assess pCR rate. pCR will be defined as no residual disease in the RP specimen by blinded central pathology review.	4 years
Minimal Residual Disease (MRD) rate	Assess the MRD rate. MRD will be defined as residual tumor focus in the RP specimen measuring ≤ 5 mm by blinded central pathology review.	4 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Surgical pathologic outcomes at RP	Evaluate surgical pathologic outcomes at RP. At the time of RP, pathologic specimens will be assessed for frequency of positive surgical margins, extracapsular extension, positive seminal vesicles, and positive lymph nodes.	During surgery
Residual Cancer Burden (RCB) at RP	Evaluate RCB at RP. Residual cancer burden will be determined as the tumor volume x tumor cellularity.	During surgery
Event Free Survival (EFS)	Evaluate EFS. EFS will be defined as the time from the date of treatment initiation to the date of first evidence of disease progression (defined below) or death from any causes, censored at the date of last disease follow-up (either PSA or imaging test): Biochemical failure (defined as a serum PSA ≥0.1 ng/mL, which is confirmed by a second determination with a PSA ≥0.1 ng/mL).; Any new evidence of metastatic disease visualized on radiographic imaging (including bone scan, CT, MRI, or positron-emission tomography).; Any new evidence of local recurrence visualized on radiographic imaging (including bone scan, CT, MRI, or positron-emission tomography).	4 years
Treatment Free Survival post RP	Evaluate treatment free survival (including adjuvant or salvage radiation therapy, ADT or other therapies) post RP. TFS will be defined as the time from the date of RP to the date of first subsequent treatment (defined below) or death from any cause, censored at the date of last disease follow-up: Adjuvant radiation therapy; Salvage radiation therapy; Prostate cancer directed systemic therapy including but not limited to ADT; Prostate cancer directed surgery or focal therapy including but not limited stereotactic radiation therapy or ablative therapy.	4 years
Pathologic Response (pCR and/or MRD) with biochemical Progression Free Survival (PFS).	Correlate pathologic response (pCR and/or MRD) with biochemical progression free survival (PFS).	4 years
Time to Testosterone Recovery post RP	Evaluate time to testosterone recovery post RP. Recovery will be defined as a testosterone level > 200 ng/dL following RP.	4 years
Assess adverse events	Type of adverse events, intensity (grading), and attribution will be evaluated. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be used to characterize safety of treatment.	2 months
Intra- and Post-Operative Complications	Peri-operative and post-operative complications will be determined via questionnaires that will be completed at time of surgery, at discharge and in the post-operative period.	4 years
Assess Cardiovascular Adverse Events	Cardiovascular adverse events will be captured via CTCAE v5 categorization.	3 years
Evaluate changes in Prostate specific antigen (PSA)	PSA kinetics will include nadir value, achieving nadir PSA < 0.2 ng/mL, achieving 50% or achieving 90% decrease in PSA from baseline, and time to PSA nadir.	4 years

Collaborators and Investigators

• Sponsor: Rana McKay, MD
• Collaborators: University of California, San Diego; AstraZeneca
• Investigators: Principal Investigator: Rana R. McKay, MD, University of California, San Diego

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2023
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: July 18, 2022
• First Submitted That Met QC Criteria: August 10, 2022
• First Posted (Actual): August 12, 2022

Study Record Updates

• Last Update Posted (Actual): January 5, 2024
• Last Update Submitted That Met QC Criteria: January 3, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Urogenital Diseases; Male Urogenital Diseases; Genital Diseases, Male; Genital Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Poly(ADP-ribose) Polymerase Inhibitors; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptive Agents, Female; Fertility Agents, Female; Fertility Agents; Luteolytic Agents; Olaparib; Leuprolide; Goserelin; Triptorelin Pamoate
• Other Study ID Numbers: HCRN GU20-436

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No